This study will evaluate the risks and benefits of treatment with a selective serotonin
reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in children and adolescents
with a pre-specified anxiety disorder, depressive disorder, eating disorder, or
obsessive-compulsive disorder.